New publication in the European Journal of Pharmaceutics and Biopharmaceutics is featuring ApidSOL™ technology and its delivery efficiency. Therapeutically relevant levels of Imiquimod (poorly soluble drug) in target tissue have been achieved with ApidSOL™ formulation despite a 100-fold dose reduction compared to a marketed product. More information here.